Response to Letter to the Editor From Binghao Zhao et al

Article Oncology

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Nicolas Girard et al.

Summary: This study analyzed the treatment characteristics and real-world progression-free survival (rwPFS) of patients receiving durvalumab, and the results showed that in patients with advanced lung cancer, rwPFS was longer in patients who received concurrent chemoradiotherapy and in patients with higher programmed cell death-ligand 1 expression.

JOURNAL OF THORACIC ONCOLOGY (2023)

Add to Collection

Article Oncology

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

David R. Spigel et al.

Summary: The study examined the efficacy of consolidation durvalumab in patients with non-small-cell lung cancer, showing significant improvements in overall survival and progression-free survival, with manageable safety. The 5-year follow-up data continued to demonstrate the positive effects of durvalumab on survival and disease progression.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial

Marina C. Garassino et al.

Summary: The study included 117 patients with advanced unresectable stage III NSCLC, showing that durvalumab after sequential CRT has a comparable safety profile to durvalumab after concurrent CRT and has promising preliminary efficacy in a frailer population.

JOURNAL OF THORACIC ONCOLOGY (2022)

Add to Collection

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

K. Park et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Article Oncology

Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer

Anne Auperin et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

Response to Letter to the Editor From Binghao Zhao et al

Related references

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer

Export Citation

Share Paper